Company record · updated August 5, 2026
Treeline Bio WTS 8/35: 14 valuation observations from SEC filings
Every row below names the filing it came from. Coverage for this company runs September 30, 2025 to March 31, 2026.
Source rails for this company: N-PORT fund mark (14).
Reported by 6 filers: T. Rowe Price All-Cap Opportunities Fund, T. Rowe Price All-Cap Opportunities Portfolio, T. Rowe Price Global Allocation Fund, T. Rowe Price Health Sciences Fund, Inc., T. Rowe Price Health Sciences Portfolio, T. Rowe Price New Horizons Fund, Inc..
| As of | Measure | Value | Reported by | Tier | What the filing says | Accession |
|---|---|---|---|---|---|---|
| 2026-03-31 | price per share | 7.287 USD | T. Rowe Price All-Cap Opportunities Portfolio | VERIFIED | valUSD 17000.57 / balance 2333.0 [common / pp] | 000109926326006590 |
| 2026-03-31 | price per share | 7.287 USD | T. Rowe Price All-Cap Opportunities Fund | VERIFIED | valUSD 511620.27 / balance 70210.0 [common / pp] | 000109926326006569 |
| 2026-03-31 | price per share | 7.287 USD | T. Rowe Price Health Sciences Portfolio | VERIFIED | valUSD 18975.35 / balance 2604.0 [common / pp] | 000109926326006593 |
| 2026-03-31 | price per share | 7.287 USD | T. Rowe Price Health Sciences Fund, Inc. | VERIFIED | valUSD 327310.18 / balance 44917.0 [common / pp] | 000109926326006598 |
| 2025-12-31 | price per share | 7.287 USD | T. Rowe Price All-Cap Opportunities Fund | VERIFIED | valUSD 511620.27 / balance 70210.0 [common / pp] | 000109926326002520 |
| 2025-12-31 | price per share | 7.287 USD | T. Rowe Price All-Cap Opportunities Portfolio | VERIFIED | valUSD 17000.57 / balance 2333.0 [common / pp] | 000109926326002541 |
| 2025-12-31 | price per share | 7.287 USD | T. Rowe Price Health Sciences Portfolio | VERIFIED | valUSD 18975.35 / balance 2604.0 [common / pp] | 000109926326002544 |
| 2025-12-31 | price per share | 7.287 USD | T. Rowe Price Health Sciences Fund, Inc. | VERIFIED | valUSD 327310.18 / balance 44917.0 [common / pp] | 000109926326002549 |
| 2025-12-31 | price per share | 7.287 USD | T. Rowe Price New Horizons Fund, Inc. | VERIFIED | valUSD 442882.0 / balance 60777.0 [common / pp] | 000109926326002508 |
| 2025-10-31 | price per share | 7.287 USD | T. Rowe Price Global Allocation Fund | VERIFIED | valUSD 1246.08 / balance 171.0 [common / pp] | 000109926325005062 |
| 2025-09-30 | price per share | 7.287 USD | T. Rowe Price All-Cap Opportunities Portfolio | VERIFIED | valUSD 17000.57 / balance 2333.0 [common / pp] | 000109926325003634 |
| 2025-09-30 | price per share | 7.287 USD | T. Rowe Price All-Cap Opportunities Fund | VERIFIED | valUSD 511620.27 / balance 70210.0 [common / pp] | 000109926325003613 |
| 2025-09-30 | price per share | 7.287 USD | T. Rowe Price Health Sciences Fund, Inc. | VERIFIED | valUSD 327310.18 / balance 44917.0 [common / pp] | 000109926325003642 |
| 2025-09-30 | price per share | 7.287 USD | T. Rowe Price Health Sciences Portfolio | VERIFIED | valUSD 18975.35 / balance 2604.0 [common / pp] | 000109926325003637 |
Reading these figures
A fund mark is the filer's own fair-value estimate at a quarter end, not a transaction price, and two filers can reach different values for the same date. A charter round price is the issue price of that series at issuance. Neither is a current market price. The capabilities page states the full limits.